Shopping Cart 0
Cart Subtotal
USD 0

Generics in the United States

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Generics in the United States

Summary

Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the United States generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The US generics market had total revenues of USD 102.9bn in 2017, representing a compound annual growth rate (CAGR) of 7.6% between 2013 and 2017.

- Market consumption volume increased with a CAGR of 1.5% between 2013 and 2017, to reach a total of 91% in 2017.

- Generics' market share in the US is already very close to saturation, so growth has been slow, and even fell into decline in 2016.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United States

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States

- Leading company profiles reveal details of key generics market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the United States generics market by value in 2017?

- What will be the size of the United States generics market in 2022?

- What factors are affecting the strength of competition in the United States generics market?

- How has the market performed over the last five years?

- How large is the United States's generics market in relation to its regional counterparts?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market volume 10

Market Segmentation 11

Geography segmentation 11

Market Outlook 12

Market value forecast 12

Market volume forecast 13

Five Forces Analysis 14

Summary 14

Buyer power 15

Supplier power 16

New entrants 17

Threat of substitutes 18

Degree of rivalry 19

Leading Companies 21

Mylan N.V. 21

Novartis AG 25

Pfizer Inc. 29

Teva Pharmaceutical Industries Limited 33

Macroeconomic Indicators 36

Country data 36

Methodology 38

Industry associations 39

Related MarketLine research 39

Appendix 40

About MarketLine 40


List Of Figure

List of Figures

Figure 1: United States generics market value: USD billion, 2013-17

Figure 2: United States generics market volume: % of total pharma, 2013-17

Figure 3: United States generics market geography segmentation: % share, by value, 2017

Figure 4: United States generics market value forecast: USD billion, 2017-22

Figure 5: United States generics market volume forecast: % of total pharma, 2017-22

Figure 6: Forces driving competition in the generics market in the United States, 2017

Figure 7: Drivers of buyer power in the generics market in the United States, 2017

Figure 8: Drivers of supplier power in the generics market in the United States, 2017

Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2017

Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2017

Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2017

Figure 12: Mylan N.V.: revenues & profitability

Figure 13: Mylan N.V.: assets & liabilities

Figure 14: Novartis AG: revenues & profitability

Figure 15: Novartis AG: assets & liabilities

Figure 16: Pfizer Inc.: revenues & profitability

Figure 17: Pfizer Inc.: assets & liabilities

Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities


List Of Table

List of Tables

Table 1: United States generics market value: USD billion, 2013-17

Table 2: United States generics market volume: % of total pharma, 2013-17

Table 3: United States generics market geography segmentation: USD billion, 2017

Table 4: United States generics market value forecast: USD billion, 2017-22

Table 5: United States generics market volume forecast: % of total pharma, 2017-22

Table 6: Mylan N.V.: key facts

Table 7: Mylan N.V.: key financials (USD )

Table 8: Mylan N.V.: key financial ratios

Table 9: Novartis AG: key facts

Table 10: Novartis AG: key financials (USD )

Table 11: Novartis AG: key financial ratios

Table 12: Pfizer Inc.: key facts

Table 13: Pfizer Inc.: key financials (USD )

Table 14: Pfizer Inc.: key financial ratios

Table 15: Teva Pharmaceutical Industries Limited: key facts

Table 16: Teva Pharmaceutical Industries Limited: key financials (USD )

Table 17: Teva Pharmaceutical Industries Limited: key financial ratios

Table 18: United States size of population (million), 2013-17

Table 19: United States gdp (constant 2005 prices, USD billion), 2013-17

Table 20: United States gdp (current prices, USD billion), 2013-17

Table 21: United States inflation, 2013-17

Table 22: United States consumer price index (absolute), 2013-17

Table 23: United States exchange rate, 2013-17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Generics, MarketLine, United States


Companies

Mylan N.V.

Novartis AG

Pfizer Inc.

Teva Pharmaceutical Industries Limited